Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates prolonged survival and peripheral nerve remyelination in Krabbe disease mice, highlighting the need for blood-brain barrier penetration in central manifestations.
The twitcher mouse is an animal model of galactosylceramidase deficiency (Krabbe's disease), a human sphingolipidosis. The effects of hematopoietic cell transplantation as potential enzyme replacement therapy were examined in the twitcher mouse. Survival in twitcher mice with transplants was significantly prolonged and was associated with gradual repair of demyelination in peripheral nerves. In contrast, there was no improvement in the neurodegenerative process in the central nervous system after transplantation. These observations indicate that cellular transplantation may effectively provide in vivo enzyme replacement for the peripheral manifestations of genetic storage diseases. Strategies to perturb the blood-brain barrier may be necessary for enzyme replacement to be therapeutic in diseases with central nervous system manifestations.
No takes yet. Share an insight, caveat, or question.
Yeager et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: